Search

Search Constraints

You searched for: Author/Creator Flechtner, Jessica

Search Results

1. 149 GEN-011: An ATLASTM-guided peripheral-blood derived neoantigen-specific T cell therapy designed to improve on TIL approaches. (10th December 2020)

2. 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two. Issue 1 (November 2016)

3. 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two. Issue 1 (November 2016)

4. 390 Emerging safety and activity data from GEN-009–101: A phase 1/2a trial of GEN-009, a neoantigen vaccine in combination with PD-1 check-point inhibitors (CPI) in advanced solid tumors. (9th November 2020)

5. 390 Emerging safety and activity data from GEN-009–101: A phase 1/2a trial of GEN-009, a neoantigen vaccine in combination with PD-1 check-point inhibitors (CPI) in advanced solid tumors. (9th November 2020)

6. 413 GEN-009, a personalized neoantigen vaccine, elicits robust immune responses in individuals with advanced or metastatic solid tumors. (9th November 2020)

7. 413 GEN-009, a personalized neoantigen vaccine, elicits robust immune responses in individuals with advanced or metastatic solid tumors. (9th November 2020)

8. 526 InhibigenTM-specific responses suppress anti-tumor immunity and promote tumor growth. (9th November 2020)